A University of Miami team has used mitochondrion-targeted gene therapy to restore functional ND4 levels in Leber's hereditary optical neuropathy. Next steps include optimizing the approach to cover several variants of the disease and determining the therapy's potential advantages over pharmacological strategies in development.